-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Industrial chain extension or product line expansion is achieved through investment, acquisition, etc.
, which often occurs in the pharmaceutical field
.
Recently, Haoyuan Pharmaceutical plans to acquire the drug source drug for 400 million yuan, realizing another acquisition after the listing
.
According to the announcement of Haoyuan Pharmaceutical, the company plans to issue shares and pay cash to WANG YUAN (Wang Yuan), Shanghai Yuanmeng, Qidong Yuanli, and Ningbo Jiusheng to purchase 100% equity of Yaoyuan Medicine held by them.
The transaction price is not expected to exceed 420 million yuan
.
Yaoyuan Pharmaceutical, the target company to be acquired this time, is a high-tech enterprise that provides one-stop services for pharmaceutical R&D, registration and production of APIs and preparations for new drug developers, especially in the field of preparation CMC business
.
It is reported that in the past, Haoyuan Pharmaceutical’s expansion in the back-end of research and development was basically limited to the business of APIs and intermediates.
This acquisition is expected to continue to extend the service chain of Haoyuan Pharmaceuticals, make up for shortcomings, and create an “intermediate-API-formulation”.
"Integrated CRO/CDMO/CMO whole industry service platform
.
This is not the first external acquisition of Haoyuan Pharmaceutical since its listing
.
It is understood that Haoyuan Pharmaceuticals planned to use over-raised funds of 144 million yuan in October 2021 to increase capital to Hefei Ochuang Gene Biotechnology Co.
, Ltd.
90% equity of ChuangGene after the capital increase is completed
.
The capital increase this time is used for the construction of the Outron gene medicine research and development and biological reagent research and development industrialization base projects
.
According to the announcement at the time, the capital increase in Ougen Gene is in line with the company's development strategy, which is conducive to optimizing the company's industrial layout, expanding its business scale, making full use of local talent and location and other resource advantages, reducing R&D costs and production costs, and improving the company's economic benefits and comprehensive strength.
Provide a strong guarantee for the company's sustainable operation and rapid development
.
Can buy buy buy "smash" the future? This is also worthy of corporate attention
.
It is understood that there are not a few companies that expand their product lines by buying, buying and buying in the pharmaceutical field.
.
For example, Jiuqiang Biology also issued an announcement saying that it signed the "Investment Agreement on Wuhan Huihai Pharmaceutical Technology Development Co.
, Ltd.
" with Wuhan Huihai Pharmaceutical Technology Development Co.
, Ltd.
and its shareholders Xia Zhihui and Wang Ying, and agreed to transfer 4 million yuan.
Xia Zhihui and Wang Ying jointly hold 75% of Huihai Pharmaceutical
.
According to the announcement, Huihai Pharmaceutical is mainly engaged in in vitro diagnostics business, and its core business is the R&D and registration of antigen detection products
.
The acquisition of Huihai Pharmaceutical by Jiuqiang Bio will expand the product line of Jiuqiang Bio and further enhance the competitiveness and comprehensive strength of its testing business
.
In addition, recently, Jianzhijia also announced that it intends to acquire 80%-100% of the shares of Tangren Medicine held by the shareholders of Hebei Tangren Pharmaceutical Co.
,
Ltd.
According to the announcement, Jianzhijia’s acquisition plan is to achieve the purpose of holding or wholly-owned control of Tangren Pharmaceutical, in order to realize the merger and acquisition of Tangren Pharmaceutical’s chain pharmacy brand and directly-operated stores, various operating assets, operating resources and operating rights and interests, and promote the The company has expanded its business in the Bohai Rim region with Beijing-Tianjin-Hebei as the core
.
Jian Zhijia said that this transaction is in line with the national industry policy orientation and has important strategic significance to the company
.
After the transaction is completed, Tangren Pharmaceutical stores will be included in the management scope of the company, and the company will expand its business in the Bohai Rim region with Beijing-Tianjin-Hebei as the core and expand its competitive advantages
.
The industry said that with the continuous deepening of the "self-build + acquisition" two-wheel drive strategy in the future, Jianzhijia's management efficiency and efficiency will be further improved, and its performance will usher in a period of rapid growth
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
, which often occurs in the pharmaceutical field
.
Recently, Haoyuan Pharmaceutical plans to acquire the drug source drug for 400 million yuan, realizing another acquisition after the listing
.
According to the announcement of Haoyuan Pharmaceutical, the company plans to issue shares and pay cash to WANG YUAN (Wang Yuan), Shanghai Yuanmeng, Qidong Yuanli, and Ningbo Jiusheng to purchase 100% equity of Yaoyuan Medicine held by them.
The transaction price is not expected to exceed 420 million yuan
.
Yaoyuan Pharmaceutical, the target company to be acquired this time, is a high-tech enterprise that provides one-stop services for pharmaceutical R&D, registration and production of APIs and preparations for new drug developers, especially in the field of preparation CMC business
.
It is reported that in the past, Haoyuan Pharmaceutical’s expansion in the back-end of research and development was basically limited to the business of APIs and intermediates.
This acquisition is expected to continue to extend the service chain of Haoyuan Pharmaceuticals, make up for shortcomings, and create an “intermediate-API-formulation”.
"Integrated CRO/CDMO/CMO whole industry service platform
.
This is not the first external acquisition of Haoyuan Pharmaceutical since its listing
.
It is understood that Haoyuan Pharmaceuticals planned to use over-raised funds of 144 million yuan in October 2021 to increase capital to Hefei Ochuang Gene Biotechnology Co.
, Ltd.
90% equity of ChuangGene after the capital increase is completed
.
The capital increase this time is used for the construction of the Outron gene medicine research and development and biological reagent research and development industrialization base projects
.
According to the announcement at the time, the capital increase in Ougen Gene is in line with the company's development strategy, which is conducive to optimizing the company's industrial layout, expanding its business scale, making full use of local talent and location and other resource advantages, reducing R&D costs and production costs, and improving the company's economic benefits and comprehensive strength.
Provide a strong guarantee for the company's sustainable operation and rapid development
.
Can buy buy buy "smash" the future? This is also worthy of corporate attention
.
It is understood that there are not a few companies that expand their product lines by buying, buying and buying in the pharmaceutical field.
.
For example, Jiuqiang Biology also issued an announcement saying that it signed the "Investment Agreement on Wuhan Huihai Pharmaceutical Technology Development Co.
, Ltd.
" with Wuhan Huihai Pharmaceutical Technology Development Co.
, Ltd.
and its shareholders Xia Zhihui and Wang Ying, and agreed to transfer 4 million yuan.
Xia Zhihui and Wang Ying jointly hold 75% of Huihai Pharmaceutical
.
According to the announcement, Huihai Pharmaceutical is mainly engaged in in vitro diagnostics business, and its core business is the R&D and registration of antigen detection products
.
The acquisition of Huihai Pharmaceutical by Jiuqiang Bio will expand the product line of Jiuqiang Bio and further enhance the competitiveness and comprehensive strength of its testing business
.
In addition, recently, Jianzhijia also announced that it intends to acquire 80%-100% of the shares of Tangren Medicine held by the shareholders of Hebei Tangren Pharmaceutical Co.
,
Ltd.
According to the announcement, Jianzhijia’s acquisition plan is to achieve the purpose of holding or wholly-owned control of Tangren Pharmaceutical, in order to realize the merger and acquisition of Tangren Pharmaceutical’s chain pharmacy brand and directly-operated stores, various operating assets, operating resources and operating rights and interests, and promote the The company has expanded its business in the Bohai Rim region with Beijing-Tianjin-Hebei as the core
.
Jian Zhijia said that this transaction is in line with the national industry policy orientation and has important strategic significance to the company
.
After the transaction is completed, Tangren Pharmaceutical stores will be included in the management scope of the company, and the company will expand its business in the Bohai Rim region with Beijing-Tianjin-Hebei as the core and expand its competitive advantages
.
The industry said that with the continuous deepening of the "self-build + acquisition" two-wheel drive strategy in the future, Jianzhijia's management efficiency and efficiency will be further improved, and its performance will usher in a period of rapid growth
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
